MEDIA_REFRESH_DATA_PRESS_RELEASE
Media
U.S. News Room
Press Releases
Daiichi Sankyo Establishes “Smart” Research Laboratory in San Diego to Expedite Drug Discovery
Download the PDF version of Article
January 21, 2025
Tokyo and Basking Ridge, NJ - (January 21, 2025) - Daiichi Sankyo (TSE: 4568) has established a state-of-the-art research laboratory in San Diego, California, U.S., dedicated to the development of robotics, automation and sophisticated software to improve and expedite its overall drug discovery efforts.
Technology developed at the new laboratory will automate drug discovery tasks that generate data for downstream analysis. The laboratory will develop a comprehensive collection of software and hardware tools to collect massive amounts of data necessary to generate potential drug candidates faster and to support AI-based approaches in drug discovery, enhancing Daiichi Sankyo’s capability to innovate.
“Ultimately, Daiichi Sankyo aims to accelerate the development of life-changing medicines and deliver them to patients around the world as quickly and efficiently as possible,” said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo. “By leveraging the extensive data collected by our autonomous robotics that operate continuously and cutting-edge software for automated orchestration and data management, the laboratory is set to revolutionize our research processes as it will not only achieve unprecedented levels of repeatability and productivity but also enable our scientists to concentrate on intellectual advancements and leverage AI-based analytical tools.”
About Daiichi Sankyo
Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit http://www.daiichisankyo.com/.
Media Contacts:
Global/US:
|
Japan: Investor Relations Contact: |